v3 Template
A

Allogene Therapeutics Inc.

Biotechnology / Healthcare South San Francisco, California ~640 employees
Founded
--
Employees (Est.)
~640
32 leaders known
Total Funding
$125.0M
Funding Rounds
2
Last Funding
2024-05-13

About Allogene Therapeutics Inc.

Allogene Therapeutics is dedicated to redefining the future of cell therapy by developing and delivering the first allogeneic CAR T cell (AlloCAR T™) products for blood cancers, solid tumors, and autoimmune diseases. Their mission is to lead the next revolution in cell therapy with innovative, scalable, and accessible treatments.

Products & Services

AlloCAR T™ Product Platform:A pioneering platform for allogeneic CAR T cell therapies featuring multiplex gene-engineering, gene-editing capabilities, proprietary lymphodepletion, and state-of-the-art manufacturing.
Cemacabtagene Ansegedleucel (Cema-Cel):Frontline treatment for large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), currently in the ALPHA3 Phase 2 trial.
ALLO-316:Therapy for advanced renal cell carcinoma (ccRCC) with durable responses in heavily pretreated patients.
ALLO-329:Next-generation dual-targeted CD19/CD70 allogeneic CAR T therapy for autoimmune diseases like lupus, myositis, and scleroderma.

Specialties

Allogeneic CAR T Cell Therapy Cell Therapy Innovation Gene Engineering and Editing Lymphodepletion Platforms Scalable Manufacturing Blood Cancers Solid Tumors Autoimmune Diseases

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Underwritten Offering
T: -
FT: Underwritten Offering
A: 110000000
MR: -
FA: 110 million
FAN: 110000000
D: 2024-05-13
FD: 2024-05-13
3 investors
2 RT: Grant
T: -
FT: Grant
A: 15000000
MR: -
FA: $15 million
FAN: 15000000
D: 2024-04-26
FD: 2024-04-26
1 investors
Underwritten Offering Latest
2024-05-13
$110.0M
3 investors (Pro only)
Grant 2024-04-26
$15.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

A

Arie Belldegrun

Executive Chairman and Co-Founder

D

David Chang

President, Chief Executive Officer and Co-Founder

B

Benjamin M. Beneski

Senior Vice President, Chief Technical Officer

C

Christine Cassiano

Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer

E

Earl Douglas

General Counsel and Compliance Officer of Allogene

S

Susie Lundeen

Chief People Officer

View 29 more team members with Pro

Unlock Full Team Directory

Recent News

Allogene Therapeutics Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Healthcare
Company Size
~640 employees (est.)
Locations
South San Francisco, California
South San Francisco, Calif.

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro